Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz Faces US Denosumab Lawsuit Ahead Of Key 2025 Patent Expiry

Sandoz’s BLA Accepted For FDA Review In February; Denosumab Sales In Billions

Executive Summary

Months after announcing that its GP2411 biosimilar denosumab candidate was accepted for filing by the FDA, Sandoz has been sued for alleged patent infringement by originator Amgen.

You may also be interested in...



Sandoz Gets US Denosumab Approvals – But When Will They Launch?

Sandoz has received the first FDA approvals for denosumab biosimilar rivals to Prolia and Xgeva under the names Wyost and Jubbonti. However, the firm has declined to comment on launch details while it remains locked in litigation with originator Amgen.

Henlius Raises Stakes In Denosumab Race With Phase I Completion

Shanghai Henlius Biotech announced the successful completion of a Phase I study of its biosimilar HLX14 to Prolia/Xgeva, paving the way for EU and US approval applications later in 2024.

What’s Next? Five Things To Look Out For In December

Generics Bulletin previews the most noteworthy and anticipated events for December 2023.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152692

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel